Umoja Biopharma said it is delaying the first clinical readout from its China‑based in vivo CAR‑T trial. The company did not provide a new disclosure date but acknowledged the postponement will push back investor expectations and program milestones tied to the initial efficacy signal. Umoja’s platform — designed to generate CAR‑T potency by in vivo editing or delivery — has been closely watched because successful clinical validation could materially lower manufacturing complexity and costs for adoptive cell therapies. The delay raises questions about operational execution and regulatory timelines for in vivo approaches, which remain technically and clinically nascent. Competitors and partners working on in vivo T‑cell programming will reassess launch timing and de‑risking strategies; investors will look for clarity on the causes of the delay and revised milestones.